Sionna Therapeutics (SION) Competitors $12.90 +0.87 (+7.23%) As of 05/1/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesSEC FilingsTrendsBuy This Stock SION vs. DNLI, APLS, AAPG, KYMR, VCEL, MIRM, BEAM, GMTX, BHC, and TARSShould you be buying Sionna Therapeutics stock or one of its competitors? The main competitors of Sionna Therapeutics include Denali Therapeutics (DNLI), Apellis Pharmaceuticals (APLS), Ascentage Pharma Group International (AAPG), Kymera Therapeutics (KYMR), Vericel (VCEL), Mirum Pharmaceuticals (MIRM), Beam Therapeutics (BEAM), Gemini Therapeutics (GMTX), Bausch Health Companies (BHC), and Tarsus Pharmaceuticals (TARS). These companies are all part of the "pharmaceutical products" industry. Sionna Therapeutics vs. Denali Therapeutics Apellis Pharmaceuticals Ascentage Pharma Group International Kymera Therapeutics Vericel Mirum Pharmaceuticals Beam Therapeutics Gemini Therapeutics Bausch Health Companies Tarsus Pharmaceuticals Sionna Therapeutics (NASDAQ:SION) and Denali Therapeutics (NASDAQ:DNLI) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, community ranking, dividends, risk, earnings, media sentiment and valuation. Is SION or DNLI more profitable? Sionna Therapeutics' return on equity of 0.00% beat Denali Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Sionna TherapeuticsN/A N/A N/A Denali Therapeutics N/A -32.94%-30.04% Does the media refer more to SION or DNLI? In the previous week, Denali Therapeutics had 6 more articles in the media than Sionna Therapeutics. MarketBeat recorded 9 mentions for Denali Therapeutics and 3 mentions for Sionna Therapeutics. Denali Therapeutics' average media sentiment score of 1.41 beat Sionna Therapeutics' score of 0.76 indicating that Denali Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sionna Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Denali Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders have more ownership in SION or DNLI? 92.9% of Denali Therapeutics shares are held by institutional investors. 7.9% of Denali Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has stronger valuation & earnings, SION or DNLI? Sionna Therapeutics has higher earnings, but lower revenue than Denali Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSionna TherapeuticsN/AN/AN/AN/AN/ADenali Therapeutics$330.53M7.06-$145.22M-$2.57-6.25 Do analysts rate SION or DNLI? Sionna Therapeutics presently has a consensus price target of $38.50, indicating a potential upside of 198.45%. Denali Therapeutics has a consensus price target of $37.57, indicating a potential upside of 133.94%. Given Sionna Therapeutics' higher possible upside, analysts plainly believe Sionna Therapeutics is more favorable than Denali Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sionna Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Denali Therapeutics 0 Sell rating(s) 1 Hold rating(s) 14 Buy rating(s) 2 Strong Buy rating(s) 3.06 Does the MarketBeat Community favor SION or DNLI? Denali Therapeutics received 464 more outperform votes than Sionna Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Sionna Therapeutics an outperform vote while only 68.58% of users gave Denali Therapeutics an outperform vote. CompanyUnderperformOutperformSionna TherapeuticsOutperform Votes3100.00% Underperform VotesNo VotesDenali TherapeuticsOutperform Votes46768.58% Underperform Votes21431.42% SummaryDenali Therapeutics beats Sionna Therapeutics on 9 of the 13 factors compared between the two stocks. Get Sionna Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SION and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SION vs. The Competition Export to ExcelMetricSionna TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$569.20M$6.85B$5.54B$7.93BDividend YieldN/A2.96%5.09%4.23%P/E RatioN/A7.3222.5718.54Price / SalesN/A241.43399.89103.29Price / CashN/A65.8538.1834.62Price / BookN/A6.486.774.25Net IncomeN/A$143.41M$3.22B$248.18M7 Day Performance6.26%1.91%1.07%0.91%1 Month Performance9.04%4.28%2.46%2.58%1 Year PerformanceN/A-3.87%15.74%4.02% Sionna Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SIONSionna TherapeuticsN/A$12.90+7.2%$38.50+198.4%N/A$569.20MN/A0.0035Positive NewsGap DownDNLIDenali Therapeutics4.1558 of 5 stars$15.19+2.2%$37.57+147.3%-0.6%$2.21B$330.53M-5.52430Upcoming EarningsAPLSApellis Pharmaceuticals4.1321 of 5 stars$17.54+0.3%$45.35+158.5%-56.4%$2.21B$781.37M-8.67770Upcoming EarningsAnalyst ForecastAnalyst RevisionAAPGAscentage Pharma Group InternationalN/A$25.00+4.6%N/AN/A$2.18B$980.65M0.00600KYMRKymera Therapeutics2.0009 of 5 stars$32.55+6.0%$56.36+73.1%-4.7%$2.12B$47.07M-13.94170Upcoming EarningsNews CoveragePositive NewsVCELVericel2.3112 of 5 stars$39.67-0.9%$60.86+53.4%-19.5%$1.99B$237.22M661.28300Upcoming EarningsPositive NewsMIRMMirum Pharmaceuticals4.2422 of 5 stars$39.74+0.3%$58.20+46.5%+68.8%$1.98B$336.89M-19.78140Upcoming EarningsPositive NewsBEAMBeam Therapeutics3.0896 of 5 stars$19.63-1.2%$49.45+151.9%-8.8%$1.96B$63.52M-11.16510Upcoming EarningsShort Interest ↑News CoverageGMTXGemini TherapeuticsN/A$45.15+2.6%N/A+73.2%$1.96BN/A-45.1530High Trading VolumeBHCBausch Health Companies4.1781 of 5 stars$5.32+2.8%$7.17+34.8%-39.5%$1.96B$9.63B-44.2919,900Analyst UpgradeTARSTarsus Pharmaceuticals2.0699 of 5 stars$50.16+0.3%$63.67+26.9%+54.8%$1.92B$182.95M-13.1750Earnings ReportUpcoming EarningsNews CoveragePositive News Related Companies and Tools Related Companies DNLI Alternatives APLS Alternatives AAPG Alternatives KYMR Alternatives VCEL Alternatives MIRM Alternatives BEAM Alternatives GMTX Alternatives BHC Alternatives TARS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SION) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sionna Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sionna Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
